
We had big movements in two stocks in the biotech/healthcare space. One was Abbvie (ABBV), whose stock was hammered late in the trading session after it was announced that the California Department. Of Insurance is suing the company over alleged kickbacks in the promotion of Humira. Meanwhile, Viking Therapeutics (VKTX) was up dramatically on successfully meeting endpoints for its phase 2 study of VK2809. Here’s an overview of both stocks and what we’re looking for going forward.